Teva Pharmaceutical Industries - TEVA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.88
  • Forecasted Upside: 5.07%
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.01 (0.10%)

This chart shows the closing price for TEVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TEVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEVA

Analyst Price Target is $10.88
▲ +5.07% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is $10.88, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 5.07% upside from the last price of $10.35.

This chart shows the closing price for TEVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Teva Pharmaceutical Industries. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2023UBS GroupBoost TargetNeutral ➝ Neutral$8.00 ➝ $11.00Low
9/8/2023Bank of AmericaBoost TargetBuy ➝ Buy$12.00 ➝ $13.00Low
7/6/2023UBS GroupUpgradeSell ➝ Neutral$7.00 ➝ $8.00Low
5/25/2023Morgan StanleyInitiated CoverageEqual Weight$10.00Low
5/18/2023Evercore ISIUpgradeIn-Line ➝ OutperformLow
2/9/2023BarclaysBoost TargetOverweight$13.00 ➝ $14.00Low
1/19/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $12.00Low
11/23/2022Piper SandlerLower TargetUnderweight$8.00 ➝ $7.00Low
11/14/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$11.00 ➝ $10.00Low
11/7/2022BMO Capital MarketsLower TargetMarket Perform$11.00 ➝ $10.00Low
11/4/2022UBS GroupDowngradeNeutral ➝ SellLow
10/21/2022Jefferies Financial GroupReiterated RatingBuy$10.00Low
8/5/2022Bank of AmericaUpgradeNeutral ➝ Buy$10.00 ➝ $13.00Low
8/2/2022The Goldman Sachs GroupBoost TargetNeutral$9.00 ➝ $10.00Low
6/13/2022UBS GroupInitiated CoverageNeutral$10.00Low
5/17/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$9.00N/A
5/4/2022Piper SandlerDowngradeNeutral ➝ Underweight$11.00 ➝ $7.00Low
4/5/2022BarclaysUpgradeEqual Weight ➝ Overweight$11.00 ➝ $13.00N/A
3/25/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$11.00Medium
2/18/2022BarclaysLower TargetEqual Weight$13.00 ➝ $11.00Medium
1/27/2022ArgusDowngradeBuy ➝ HoldMedium
10/28/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
7/29/2021Raymond JamesLower TargetOutperform$15.00 ➝ $14.00Medium
7/29/2021Wells Fargo & CompanyLower TargetEqual Weight$12.00 ➝ $11.00Medium
5/10/2021UBS GroupReiterated RatingBuy ➝ Neutral$15.00 ➝ $11.00N/A
5/4/2021UBS GroupDowngradeBuy ➝ Neutral$15.00 ➝ $11.00High
3/14/2021JPMorgan Chase & Co.Reiterated RatingHold$10.00Medium
12/28/2020Raymond JamesReiterated RatingBuyN/A
11/24/2020OppenheimerInitiated CoverageMarket PerformLow
11/6/2020BMO Capital MarketsLower TargetMarket Perform$13.00 ➝ $11.00High
10/23/2020Raymond JamesReiterated RatingBuyLow
10/13/2020ArgusLower TargetAverage ➝ Buy$14.00 ➝ $11.00Low
9/14/2020Raymond JamesReiterated RatingBuyLow
8/26/2020Bank of AmericaReiterated RatingSell$8.00Low
8/6/2020SVB LeerinkBoost TargetMarket Perform$13.00 ➝ $14.00Medium
8/6/2020BarclaysUpgradeUnderweight ➝ Equal Weight$10.00 ➝ $13.00Medium
7/27/2020The Goldman Sachs GroupInitiated CoverageNeutral$12.00Low
6/1/2020SunTrust BanksUpgradeHold ➝ Buy$11.00 ➝ $16.00High
5/11/2020UBS GroupBoost TargetBuy$12.00 ➝ $15.00Medium
5/8/2020Cantor FitzgeraldReiterated RatingNeutralLow
5/8/2020SVB LeerinkBoost TargetMarket Perform$11.00 ➝ $12.00Low
5/8/2020Bank of AmericaReiterated RatingUnderperform$7.00 ➝ $8.00Low
4/24/2020CitigroupInitiated CoverageNeutralLow
4/17/2020BarclaysReiterated RatingSell$9.00Low
4/15/2020Piper SandlerLower TargetNeutral$10.00 ➝ $8.00Low
4/6/2020UBS GroupUpgradeNeutral ➝ Buy$14.00 ➝ $12.00High
4/2/2020Morgan StanleyLower TargetUnderweight$13.00 ➝ $8.00Medium
3/23/2020Bank of AmericaLower TargetUnderperform$11.00 ➝ $7.00Low
3/5/2020Wells Fargo & CompanyBoost TargetEqual Weight$10.00 ➝ $12.00Low
2/24/2020Edward JonesDowngradeHold ➝ SellHigh
2/18/2020ArgusBoost TargetBuy$10.00 ➝ $15.00Low
2/17/2020UBS GroupBoost TargetNeutral$8.00 ➝ $14.00Medium
2/14/2020Morgan StanleyBoost TargetUnderweight$8.00 ➝ $13.00High
2/13/2020Bank of AmericaBoost TargetUnderperform$8.00 ➝ $11.00High
2/13/2020SunTrust BanksBoost TargetHold$9.00 ➝ $13.00Medium
2/13/2020OppenheimerBoost TargetOutperform$12.00 ➝ $16.00High
2/12/2020Cantor FitzgeraldBoost TargetIn-Line ➝ Neutral$9.00 ➝ $15.00Low
2/12/2020CfraBoost TargetHold$11.00 ➝ $13.00Low
1/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$8.00 ➝ $10.00Medium
1/3/2020Bank of AmericaUpgradeUnderperform ➝ BuyHigh
11/12/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$8.00Medium
10/16/2019GabelliUpgradeHold ➝ BuyHigh
9/30/2019Wells Fargo & CompanyLower TargetMarket Perform$17.00 ➝ $8.00Low
9/12/2019GuggenheimInitiated CoverageNeutralLow
9/6/2019JPMorgan Chase & Co.Lower TargetUnderweight$9.00 ➝ $7.00Low
8/16/2019UBS GroupSet TargetHold$8.00High
8/9/2019BMO Capital MarketsLower TargetMarket Perform$11.00 ➝ $9.00N/A
8/8/2019Royal Bank of CanadaReiterated RatingHold$10.00High
8/8/2019SunTrust BanksLower TargetHold$7.00Medium
8/8/2019Raymond JamesLower TargetOutperform$22.00 ➝ $15.00Medium
8/7/2019CowenSet TargetHold$9.00Low
7/19/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer Perform$9.00Low
7/15/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$16.00 ➝ $6.00High
7/10/2019Credit Suisse GroupReiterated RatingNeutralLow
7/5/2019ArgusUpgradeHold ➝ Buy$12.00High
6/18/2019Sanford C. BernsteinLower TargetMarket Perform$17.00 ➝ $11.00Medium
6/17/2019MizuhoSet TargetHold$11.00Medium
6/17/2019CitigroupSet TargetBuy$23.00 ➝ $13.00Low
6/12/2019OppenheimerSet TargetBuy$12.00High
6/12/2019Cantor FitzgeraldLower TargetNeutral$16.00 ➝ $9.00Low
6/11/2019BarclaysInitiated CoverageUnderweight ➝ Underweight$8.00Medium
6/3/2019CIBCUpgradeMarket Perform ➝ Outperform$12.00Medium
6/3/2019OppenheimerUpgradeMarket Perform ➝ Outperform$12.00Low
5/30/2019Bank of AmericaDowngradeBuy ➝ Underperform$19.00 ➝ $9.00High
5/28/2019Wells Fargo & CompanySet TargetHold$17.00Medium
5/28/2019UBS GroupDowngradeBuy ➝ Neutral$22.00 ➝ $12.00High
5/10/2019Wells Fargo & CompanyReiterated RatingHoldHigh
5/9/2019Wells Fargo & CompanyLower TargetMarket Perform$18.00 ➝ $17.00Low
5/3/2019Royal Bank of CanadaSet TargetHold$19.00Low
5/3/2019BMO Capital MarketsSet TargetHold$17.00Low
5/3/2019Morgan StanleySet TargetHold$16.00Low
5/3/2019Cantor FitzgeraldBoost TargetPositive ➝ Neutral$16.00 ➝ $25.00Medium
5/2/2019Maxim GroupReiterated RatingHoldLow
4/11/2019CitigroupLower TargetBuy$27.00 ➝ $23.00Low
4/3/2019Wells Fargo & CompanyLower TargetMarket Perform ➝ Market Perform$20.00 ➝ $18.00Low
3/28/2019BMO Capital MarketsInitiated CoverageMarket Perform$18.00Medium
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$17.00Low
3/7/2019UBS GroupInitiated CoverageBuy$22.00Medium
3/6/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00High
2/20/2019MizuhoDowngradeBuy ➝ Neutral$25.00 ➝ $18.00Medium
2/14/2019Credit Suisse GroupLower TargetNeutral ➝ Neutral$26.00 ➝ $20.00Medium
2/14/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$22.00Medium
2/14/2019Maxim GroupReiterated RatingHoldMedium
2/14/2019Wells Fargo & CompanyReiterated RatingHold$24.00 ➝ $20.00Medium
2/11/2019OppenheimerReiterated RatingHoldMedium
2/5/2019Credit Suisse GroupReiterated RatingHold$26.00High
2/5/2019HSBCSet TargetSell$12.00High
2/5/2019Bank of AmericaReiterated RatingBuy$24.00Low
1/23/2019Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$15.00 ➝ $16.00Low
1/23/2019UBS GroupUpgradeNeutral ➝ BuyLow
1/3/2019Bank of AmericaUpgradeUnderperform ➝ Buy$16.12High
12/13/2018Credit Suisse GroupSet TargetHold$26.00Medium
11/7/2018OppenheimerReiterated RatingHoldMedium
11/5/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$20.00 ➝ $27.00Low
11/2/2018Bank of AmericaBoost TargetUnderperform ➝ Underperform$19.00 ➝ $20.00Low
11/2/2018Royal Bank of CanadaSet TargetHold$22.00Low
11/2/2018Wells Fargo & CompanyReiterated RatingHoldLow
11/1/2018Maxim GroupReiterated RatingHoldHigh
11/1/2018OppenheimerReiterated RatingHoldHigh
10/17/2018Wells Fargo & CompanySet TargetHold$23.00Low
10/17/2018OppenheimerReiterated RatingHoldMedium
10/14/2018Credit Suisse GroupSet TargetHold$26.00Medium
10/1/2018The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$30.00High
10/1/2018SVB LeerinkUpgradeUnderperform ➝ Market Perform$16.00 ➝ $24.00High
9/27/2018Wells Fargo & CompanySet TargetHold$23.00Low
9/27/2018Cantor FitzgeraldReiterated RatingHold$25.00High
(Data available from 9/23/2018 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 10 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 24 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
  • 8 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $10.35
Low: $10.32
High: $10.54

50 Day Range

MA: $9.49
Low: $8.03
High: $10.70

52 Week Range

Now: $10.35
Low: $7.09
High: $11.44


7,139,257 shs

Average Volume

7,759,255 shs

Market Capitalization

$11.60 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

The following sell-side analysts have issued research reports on Teva Pharmaceutical Industries in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Piper Sandler,, and UBS Group AG.
View the latest analyst ratings for TEVA.

What is the current price target for Teva Pharmaceutical Industries?

8 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. Their average twelve-month price target is $10.88, suggesting a possible upside of 5.1%. Barclays PLC has the highest price target set, predicting TEVA will reach $14.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Teva Pharmaceutical Industries in the next year.
View the latest price targets for TEVA.

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries currently has 2 sell ratings, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TEVA, but not buy more shares or sell existing shares.
View the latest ratings for TEVA.

What other companies compete with Teva Pharmaceutical Industries?

How do I contact Teva Pharmaceutical Industries' investor relations team?

Teva Pharmaceutical Industries' physical mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company's listed phone number is (723) 914-8213 and its investor relations email address is [email protected]. The official website for Teva Pharmaceutical Industries is Learn More about contacing Teva Pharmaceutical Industries investor relations.